Aug 29, 2019 11:46 JST

Source: Eisai

Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action
Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings

TOKYO, Aug 29, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.

ETAK, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component of ETAK chemically binds the antimicrobial component to the area wiped with ETAK Antimicrobial Wet Wipes, preserving an antimicrobial effect that lasts for one week.

Eliminating virus and bacteria is a familiar and highly interested theme for consumers, especially mothers with small children.

There were many requests from mothers with small children such as "I want to use ETAK product not only inside the house but also the outside" and "I want to use ETAK product conveniently to the difficult to spray area. In response to these requests, ETAK Antimicrobial Wet Wipes has been commercialized. ETAK Antimicrobial Wet Wipes is alcohol-free so that it is easy to use for families with small children, and it can be used for elimination of viruses and bacteria on personal belongings as well as for cleaning hands and fingertips. In addition, wiping with this product can have antimicrobial barrier for personal belongings and prepare for virus and bacteria. The effect remains even if the area is wiped with water."

As the ETAK brand, containing long-acting antimicrobial agent ETAK, Eisai is marketing ETAK Antimicrobial Spray, a spray for mouth masks, which eliminates viruses and bacteria for 24 hours and ETAK Antimicrobial Spray alpha which can be used for a variety of lifestyle supplies including fabrics such as clothes and stuffed toys as well as kitchenware.

The addition of ETAK Antimicrobial Wet Wipes to the product lineup of ETAK brand will propose new options for elimination of viruses and bacteria as well as antimicrobial action, and we will contribute to further improvement of benefits of consumers who wish to keep those viruses and bacteria at bay.

*This product is not effective on all types of virus and bacteria.
*This product is not a pharmaceutical product nor a quasi-pharmaceutical product.
*ETAK is a registered trademark of CampusMedico Co., Ltd.

About Long-acting Antimicrobial Agent ETAK

ETAK was developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented long-acting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as an adhesive. ETAK chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect on the surface of the target object.

Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
April 18 2024 09:53 JST
 
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
April 17 2024 15:17 JST
 
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
April 03 2024 15:24 JST
 
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
April 01 2024 08:39 JST
 
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
March 29 2024 14:51 JST
 
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
March 29 2024 14:19 JST
 
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
March 29 2024 13:32 JST
 
Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
More Press release >>

Latest Press Release


More Latest Release >>